Stenotrophomonas maltophilia isolates in a tertiary care hospital in Northeastern Brazil / Isolados de Stenotrophomonas maltophilia em um hospital terciário no nordeste do Brasil

Marcela Coelho de Lemos, Erika Falcão da Paixão, Mário Anderson Rodrigues de Souza Santos, Tatiana de Aguiar Santos Vilella, Jorge Belém Oliveira Júnior, Maria da Conceição Cavalcanti de Lira, Sylvia Maria de Lemos Hinrichsen, Reginaldo Gonçalves de Lima Neto

Abstract


Introduction: Stenotrophomonas maltophilia (S.maltophilia) has emerged as an important opportunistic, nosocomial pathogen capable of causing respiratory, bloodstream and urinary infections in a debilitated host. Prevention of acquisition and infection depends upon the application of modern infection-control practices. Methods: We conducted a retrospective and observational laboratory-based study on S. maltophilia to evaluate the distribution of these pathogen isolates between February 2008 and December 2012 in a 38-bed intensive care unit in northeastern Brazil. The study began by surveying all positive S. maltophilia cultures processed by the microbiology laboratory during the period of study. The cultures, originating from various types of biological material were processed by Vitek® System. The cultures were processed in protocol in accordance with CLSI -M100- S25. The incidence rate was calculated per 1,000 admissions. Results: A total of 100 sample isolates were tested positive for S. maltophilia. The isolates were obtained from 50.301 hospitalized patients (0.19%). A total of 8.572 positive cultures were detected in different biological materials. Ninety four (94%) isolates were from patients in adult intensive care. Seventy (70%) S. maltophilia isolates were from tracheal cultures. All S. maltophilia isolates were sensitive to Co-trimoxazole and levofloxacin. Conclusions: This study shows the importance of other analytical epidemiologic studies that correlate the presence of S. maltophilia incidence associated with the risk factor, and the outcomes, in our region.

 


Keywords


Stenotrophomonas maltophilia isolates; nosocomial infection control; multidrug resistance.

Full Text:

PDF

References


Canzi KR, Colacite J. Pneumonia frequency associated to mechanical ventilation based on quantitative results of tracheal secretions. RBAC 2016; 48(2): 118-22.

Denton M, Kerr KG. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev 1998; 11(1): 57-80.

Jeon YD, Jeong WY, Kim MH, Jung IY, Ahn MY, Ann HW, et al. Risk factors for mortality in patients with Stenotrophomonas maltophilia bacteremia. Medicine 2016; 95(31): e4375.

Gales AC, Jones RN, Forward KR, Linares J, Sader HS, Verhoef J. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999). Clin Infect Dis 2001, 32 Suppl 2:S104-113.

Gopalakrishnan R, Hawley HB, Czachor JS, Markert RJ, Bernstein JM. Stenotrophomonas maltophilia infection and colonization in the intensive care units of two community hospitals: A study of 143 patients. Heart Lung 1999; 28(2): 134-141.

Neela V, Rankouhi SZ, Van Belkum A, Goering RV, Awang R. Stenotrophomonas maltophilia in Malaysia: molecular epidemiology and trimethoprim –sulfamethoxazole resistance. Inter J Infec Dis 2012; 16(8): e 603-607.

Nseir S, Di Pompeo C, Brisson H, Dewavrin F, Tissier S, Diarra M, et al. Intensive care unit-acquired Stenotrophomonas maltophilia: incidence, risk factors and outcome. Critical Care 2006, 10(5): R143.

Rodrigues LS, Di Gioia TSR, Rossi F. Stenotrophomonas maltophilia: resistência emergente ao SMX-TMP em isolados brasileiros. Uma realidade? J Bras Patol Med Lab 2011; 47(5): 511-17.

Senol E. Stenotrophomonas maltophilia: the significance and role as a nosocomial pathogen. J Hosp Infect 2004; 57(1): 1-7.

Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fifth Informational Supplement (M100-S25). Wayne, PA: CLSI, 2015.

Ebara H, Hagiya H, Haruki Y, Kondo E, Otsuka F. Clinical characteristics of Stenotrophomonas maltophilia bacteremia: a regional report and a review of a Japanese case series. Intern Med 2017; 56(2): 137-142.

Sun E, Liang G, Wang L, Wei W, Lei M, Song S, et al. Antimicrobial susceptibility of hospital acquired Stenotrophomonas maltophilia isolate biofilms. Braz J Infec Dis 2016; 20(4): 365-73.

Tajeddin E, Rashidan M, Razaghi M, Javadi SS, Sherafat SJ, Alebouyeh M, et al. The role of the intensive care unit environment and healthcare workers in the transmission of bacteria associated with hospital acquired infections. J Infect Public Health 2016; 9(1):13-23.

Batra P, Mathur P, Misra MC. Clinical characteristics and prognostic factors of patients with Stenotrophomonas maltophilia infections. J Lab Physicians 2017; 9(2): 132-5.

Brooke JS. Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin Microb Rev 2012; 25(1): 2-41.

Corlouer C, Lamy B, Desroches M, Ramos-Vivas J, Mehiri-Zghal E, Lemenand O, et al. Stenotrophomonas maltophilia healthcare-associated infections: identification of two main pathogenic genetic backgrounds. J Hosp Infect 2017; 1-6.

Ece G, Erac B, Limoncu MH, Baysak A, Oz AT, Ceylan KC. Stenotrophomonas maltophilia Pseudo-outbreak at a University Hospital Bronchoscopy Unit in Turkey. West Indian Med J 2014; 63(1): 59-61.

Kumar S, Bandyopadhyay M, Chatterjee M, Banerjee P, Poddar S, Banerjee D. Stenotrophomonas maltophilia: Complicating treatment of ESBL UTI. Adv Biomed Res 2015; 4: 36.

O'Toole G, Kaplan HB, Kolter R. Biofilm Formation as Microbial Development. Annual Review of Microbiology. 2000. 54:49-79

Brooke J. New strategies against Stenotrophomonas maltophilia: a serious worldwide intrinsically drug-resistant opportunistic pathogen. Expert Rev Anti Infect Ther. 2014. 12:1-4.

Almeida MTGA, Bertelli ECP, Rossit ARB, Bertollo EMG, Martinez MB. Infecções hospitalares por Stenotrophomonas maltophilia: aspectos clínico-epidemiológicos, microbiológicos e de resistência antimicrobiana. Arq. Ciênc. Saúde 2005; 12(3): 141-45.

Sonnenwirth AC. Bacteremia with and without meningitis due to Yersinia enterocolitica, Edwardsiella tarda, Comamonas terrigena, and Pseudomonas maltophilia. Ann. N. Y. Acad. Sci. 1970. 174:488–502.

Crossley, K., and J. M. Matsen. Intravenous catheter-associated bacteremia: role of the diagnostic microbiology laboratory. Appl. Microbiol. 1973. 26:1006–1007.

Elting, L. S., N. Khardori, G. P. Bodey, and V. Fainstein. Nosocomial infection caused by Xanthomonas maltophilia: a case-control study of predisposing factors. Infect. Control Hosp. Epidemiol. 1990. 11:134–138.

Aoun, M., P. Van der Auwera, C. Devleeshouwer, D. Daneau, N. Seraj, F. Meunier, and J. Gerain. Bacteraemia caused by non-aeruginosa Pseudomonas species in a cancer centre. J. Hosp. Infect. 1992. 22:307–316

Khardori N, Elting L, Wong E, et al. Nosocomial infections due to Xanthomonas maltophilia (Pseudomonas maltophilia) in patients with cancer. Rev Infect Dis. 1990. 12:997.

Arpi, M., M. A. Victor, J. K. Moller, V. Jonsson, M. M. Hansen, N. A. Peterslund, and B. Bruun. Changing etiology of bacteremia in patients with hematological malignancies in Denmark. Scand. J. Infect. Dis. 1994. 26:157–162.

Davin-Regli A, Bollet C, Auffray JP, Saux P, and De Micco P. Use of random amplified polymorphic DNA for epidemiological typing of Stenotrophomonas maltophilia. J. Hosp. Infect. 1996. 32:39–50.

Tsai W-H, Hsu H-C, Shih C-H. Increased Risks of Endotracheal Tube Cuff Colonization after Prolonged Intubation. Chinese Journal of Physiology. 2014. 57:152-157.

Berg G, Ebert L, Hartmann A. The rhizosphere as a reservoir for opportunistic human pathogenic bacteria. Environmental Microbiology. 2005. 7:1673-1685.

Chang Y-T, LinC-Y, Chen Y-Hand, Hsueh P-R. Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options. Front. Microbiol.2015. 6:893.

Naidu P, Smith S. A review of 11 years of Stenotrophomonas maltophilia blood isolates at a tertiary care institute in Canada. Can J Infect Dis Med Microbiol 2012; 23(4): 165–69.

Lin YT, Huang YW, Chen SJ, Chang CW; Yang TC. The SmeYZ Efflux Pump of Stenotrophomonas maltophilia contributes to Drug Resistance, Virulence-Related Characteristics, and Virulence in Mice. Antimicrob Agents Chemother. 2015; 59(7):4067-73.

Jia W, Wang J, Xu H, Li G, Tchounwou PB. Resistance of Stenotrophomonas maltophilia to Fluoroquinolones: Prevalence in a University Hospital and Possible Mechanisms. Int J Environ Res Public Health 2015; 12(5):5177-95.




DOI: https://doi.org/10.34119/bjhrv2n4-099

Refbacks

  • There are currently no refbacks.